 Investigating the safety and the activity of Rapamycin, administered before and during preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose escalation study will be performed in three steps 2, 4 and 6 mg. Patients entered in phase II will follow the same tolerable treatment regimen as patients in phase I study. 